🔎 Trials Near Me

Početna › Prekomjerna tjelesna masa › Illinois

Kliničke studije za Prekomjerna tjelesna masa u državi Illinois

38 studija za Prekomjerna tjelesna masa traži sudionike na lokacijama u državi Illinois.

Gradovi u državi Illinois

Službeni tekst studije (engleski)

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

  • Great Lakes Clinical Trials - West Wilson Avenue /ID# 282378, Chicago
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT07752979

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

  • Charter Research LLC - Chicago, Chicago
  • Flourish Research - Chicago, Chicago
  • AMR Clinical - Chicago Oak Brook, Oak Brook
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT07685808

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

  • Christie Clinic, Champaign
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT07837973

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

  • Great Lakes Clinical Trials, Chicago
  • Clinical Investigation Spec Gurnee, Gurnee
  • Endeavor Health, Skokie
  • i još 1
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07720271

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

  • Chicago Research Center, Inc, Chicago
  • Endeavor Health, Skokie
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07668414

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  • Great Lakes Clinical Trials - Ravenswood, Chicago
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07794579

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

  • Cedar Crosse Research Center, Chicago
  • Northwestern University, Chicago
  • Endeavor Health - Family Medicine Administration, Evanston
  • i još 1
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07595549

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

  • Research Site, Champaign
  • Research Site, Chicago
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07776509

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Rush University Medical Center, Chicago
U tijeku regrutacijaFaza 3
Od 18 do 70 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06937099

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

  • Ann and Robert Lurie Children's Hospital of Chicago, Chicago
  • University of Illinois at Chicago, Chicago
U tijeku regrutacijaFaza 3
Od 6 do 17 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06672549

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  • Rush University Medical Center, Chicago
U tijeku regrutacijaFaza 3
Od 18 do 70 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06937086

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  • NorthShore University Health System, Skokie
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07282600

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  • Great Lakes Clinical Trials - Ravenswood, Chicago
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07392190

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

  • Research Site, Chicago
  • Research Site, Melrose Park
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07784270

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  • Endeavor Health-Northwest Community Healthcare, Arlington Heights
  • Eagle Clinical Research, Chicago
  • University of Chicago, Chicago
  • i još 2
U tijeku regrutacijaFaza 3
Od 45 do 99 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT07037433

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

  • Great Lakes Clinical Trials - Ravenswood, Chicago
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07353931

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  • Great Lakes Clinical Trials - Ravenswood, Chicago
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT07589608

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  • AURORA-1 Clinical Site, Schaumburg
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  • AURORA-2 Clinical Site, Schaumburg
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT07743450

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  • Elevate Clinical Research, Gurnee
  • Knownwell, Schaumburg
  • Endeavor Health, Skokie
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT07351045

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  • Great Lakes Clinical Trials - Ravenswood, Chicago
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 8. ruj 2026. · NCT06143956

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

  • Walgreens - Store 11760, Oak Park
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT07745504

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  • Kailera Clinical Site, Skokie
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT07284901

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  • Flourish Research - Great Lakes Clinical Trials, Chicago
  • Endeavor Health, Skokie
  • Evanston Premier Healthcare Research LLC, Skokie
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 3. ruj 2026. · NCT07684235

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

  • Kailera Clinical Site, Springfield
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT07284875

BRIDGE & Friends Trial

  • University of Illinois Chicago, Chicago
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 50 do 79 godina · Oba spola · Ažurirano 1. ruj 2026. · NCT07798557

Assess the Effects of Replacing Foods High in Refined Carbohydrates With Avocado on Biomarkers of Inflammation.

  • Illinois Institute of Technology, Chicago
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 21 do 74 godina · Oba spola · Ažurirano 27. kol 2026. · NCT07566325

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  • Research Site, Champaign
  • Research Site, Chicago
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT07784725

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

  • Clinical Investigation Spec Gurnee, Gurnee
  • Evanston Premier Hlthcr Res, Skokie
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 17. kol 2026. · NCT07509307

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

  • ACCOMPLISH-1 Research Site, Chicago
U tijeku regrutacijaFaza 3
Od 18 do 79 godina · Oba spola · Ažurirano 10. kol 2026. · NCT07654361

Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention

  • Jesse Brown VA Medical Center, Chicago
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 22. srp 2026. · NCT06390345

FIM+DASH: Food is Medicine Intervention to Promote Healthy Eating and Blood Pressure Control

  • Mile Square Health Center Chicago, Chicago
  • Mile Square Health Center - Auburn Gresham, Chicago
  • Mile Square Health Center - Englewood, Chicago
  • i još 1
U tijeku regrutacijaFaza 2
Sve dobne skupine · Oba spola · Ažurirano 10. srp 2026. · NCT07332741

Better Lifestyle Counseling for African American Women During Pregnancy

  • University of Illinois at Chicago, Chicago
  • University of Illinois at Chicago, Chicago
U tijeku regrutacija
Od 18 do 40 godina · Žene · Ažurirano 9. srp 2026. · NCT05234125

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

  • Northwestern Memorial Hospital, Chicago
U tijeku regrutacijaOpažajna studija
Od 18 do 70 godina · Oba spola · Ažurirano 17. ožu 2026. · NCT07207148

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

  • University of Chicago, Chicago
U tijeku regrutacijaFaza 3
Od 18 do 75 godina · Oba spola · Ažurirano 14. stu 2025. · NCT06499857

Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.